Correspondence 0001493152-23-013507 from ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc.
Date: April 25, 2023 · CIK: 0001859007 · Accession: 0001493152-23-013507

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-269442

Date

April 25, 2023

Author

ZYVERSA

Form

CORRESP

Company

ZyVersa Therapeutics, Inc.

Letter

April 25, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

F Street, N.E.

Washington, D.C. 20549

Attn: Lauren Hamill

Laura Crotty

Re: ZyVersa Therapeutics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-269442

Ladies and Gentlemen:

ZyVersa Therapeutics, Inc. hereby requests that its acceleration request dated April 21, 2023 be withdrawn. Please call Jared Kelly of Lowenstein Sandler LLP at (973) 597-2400 with any questions.

Sincerely,
ZYVERSA
THERAPEUTICS INC.

Show Raw Text

CORRESP
1
filename1.htm

April
25, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington,
D.C. 20549

    Attn:
    Lauren
                                            Hamill

    Laura
    Crotty

    Re:
    ZyVersa
    Therapeutics, Inc.

Registration
Statement on Form S-1, as amended

File
No. 333-269442

Ladies
and Gentlemen:

ZyVersa
Therapeutics, Inc. hereby requests that its acceleration request dated April 21, 2023 be withdrawn. Please call Jared Kelly of Lowenstein
Sandler LLP at (973) 597-2400 with any questions.

    Sincerely,

    ZYVERSA
    THERAPEUTICS INC.

    By:
    /s/
    Stephen Glover

    Name:
    Stephen
    Glover

    Title:
    Chief
    Executive Officer

SecProbe.io